# HIBSAGO (bepirovirsen) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/bepirovirsen

> The FDA approved HIBSAGO (bepirovirsen), sponsored by GSK plc (GSK), on October 20, 2026 for chronic hepatitis B.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is HIBSAGO (bepirovirsen) FDA approved?

Yes. The FDA approved HIBSAGO (bepirovirsen), sponsored by GSK plc (GSK), on October 20, 2026 for chronic hepatitis B. FDA novel drug approvals: "Hibsago | bepirovirsen | 10/20/2026 | To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" [Calendar and source filings](https://sec-api.dev/pdufa/bepirovirsen)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/bepirovirsen#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | HIBSAGO (bepirovirsen) |
| Codes | GSK-836, GSK3228836 |
| Sponsor | GSK plc (GSK) https://sec-api.dev/companies/gsk/catalysts |
| Indications | [chronic hepatitis b](https://sec-api.dev/indications/chronic-hepatitis-b), chb infection, [Hepatitis B](https://sec-api.dev/indications/hepatitis-b), Chronic Hepatitis B Virus Infection, [Hepatitis B, Chronic](https://sec-api.dev/indications/hepatitis-b-chronic) |
| Modality | antisense |
| FDA designations | breakthrough, fast track, priority review |

## Timeline

### August 5, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Hepatitis B, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05276297 (A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05276297

### November 3, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Hepatitis B; Hepatitis B, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05630820 (Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-03 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05630820

### November 11, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Chronic Hepatitis B; Hepatitis B, Chronic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05630807 (Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-11 (ACTUAL); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT05630807

### Jan 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2026-02-26, last confirmed 2026-04-29.
- SEC Form 10-Q (accession 0000874015-26-000177): "In January 2026, we and GSK announced positive topline results from the B-Well 1 and B-Well 2 pivotal Phase 3 studies of bepirovirsen in patients with CHB." https://www.sec.gov/Archives/edgar/data/874015/000087401526000177/form10q.htm
- SEC Form 10-K (accession 0000874015-26-000115): "In January 2026, we and GSK announced positive topline results from the B-Well 1 and B-Well 2 pivotal Phase 3 studies of bepirovirsen in patients with CHB." https://www.sec.gov/Archives/edgar/data/874015/000087401526000115/form10k.htm

### March 31, 2026: trial start

- Status: completed. Date confidence: exact. Stage: 1.
- First seen 2026-04-29, last confirmed 2026-04-29.
- SEC Form 10-Q (accession 0000874015-26-000177): "Our R&D revenue during the three months ended March 31, 2026 included a $50 million milestone payment we earned when Roche initiated a Phase 1 trial for an investigational medicine for HD and $30 million in milestone payments we earned from GSK when regulatory filings for bepirovirsen were accepted for review in Japan and the European Union, or EU." https://www.sec.gov/Archives/edgar/data/874015/000087401526000177/form10q.htm

### October 20, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: chronic hepatitis B.
- First seen 2026-10-21, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Hibsago | bepirovirsen | 10/20/2026 | To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
- openFDA Drugs@FDA: "NDA221276 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20261020, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE LLC; product HIBSAGO (BEPIROVIRSEN)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA221276%22
- SEC Form 8-K (accession 0001140361-26-040388): "On October 20, 2026, Ionis Pharmaceuticals, Inc. ("Ionis") issued a press release reporting that its partner, GSK, announced that the U.S. Food and Drug Administration ("FDA") has approved HIBSAGO™ (bepirovirsen) for the treatment of chronic hepatitis B ("CHB") virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor ("NrtI") therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid ("DNA"), and with hepatitis B virus ("HBV") surface antigen ("HBsAg") levels ≤3000 IU/ml, as determined by an FDA-authorized test." https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_8k.htm
- SEC Form 8-K (accession 0001140361-26-040388): "On October 20, 2026, Ionis reported that its partner, GSK, announced that the FDA has approved HIBSAGO™ (bepirovirsen) for the treatment of" https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001140361-26-040388): "CARLSBAD, Calif., October 20, 2026 -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago (bepirovirsen) for the treatment of chronic hepatitis B (CHB) virus infection in combination with nucleos(t)ide analogue reverse transcriptase inhibitor (NrtI) therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV deoxyribonucleic acid (DNA), and with hepatitis B virus (HBV) surface antigen (HBsAg) levels ≤3000 IU/ml, as determined by an FDA-authorized test." https://www.sec.gov/Archives/edgar/data/874015/000114036126040388/ef20084189_ex99-1.htm
- SEC Form 10-Q (accession 0000874015-26-000271): "In October 2026, we achieved a $30 million milestone payment when the FDA approved HIBSAGO for the treatment of CHB infection." https://www.sec.gov/Archives/edgar/data/874015/000087401526000271/form10q.htm

### October 26, 2026: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2026-04-28, last confirmed 2026-07-29.
- SEC Form 8-K (accession 0001654954-26-004051): "In Q1, the US FDA accepted for priority review a New Drug Application (NDA) for bepirovirsen and set 26 October 2026 as the decision goal date." https://www.sec.gov/Archives/edgar/data/1131399/000165495426004051/a2755c.htm
- SEC Form 8-K (accession 0001654954-26-003977): "October 2026 assigned by FDA as PDUFA date" https://www.sec.gov/Archives/edgar/data/1131399/000165495426003977/a1144c.htm
- SEC Form 10-Q (accession 0000874015-26-000251): "The FDA has granted Priority Review of bepirovirsen, with a PDUFA action date of October 26, 2026." https://www.sec.gov/Archives/edgar/data/874015/000087401526000251/form10q.htm
- SEC Form 10-Q (accession 0000874015-26-000177): "The FDA has granted Priority Review of bepirovirsen, with a PDUFA action date of October 26, 2026." https://www.sec.gov/Archives/edgar/data/874015/000087401526000177/form10q.htm
- FDA novel drug approvals: "Hibsago | bepirovirsen | 10/20/2026 | To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026

### Q1 2027: trial start

- Status: scheduled. Date confidence: quarter. Stage: 2.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001628280-26-070542): "expected initiation of dosing of Phase 2 study in Q1 2027 and rolling data for viral and functional cure from ELIMINATE-B2 global Phase 2 study in H2 2027" https://www.sec.gov/Archives/edgar/data/1357874/000162828026070542/ex994aasldinvestordeck_v.htm

### Apr to Jul 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hepatitis B.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06497504 (Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06497504

### April 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hepatitis B.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06497504 (Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06497504

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Chronic Hepatitis B Virus Infection; Hepatitis B.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06537414 (A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06537414

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Chronic Hepatitis B Virus Infection; Hepatitis B.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06537414 (A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-31 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT06537414

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Hepatitis B.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04954859 (Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-01-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04954859

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Hepatitis B.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT04954859 (Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-01-24 (ESTIMATED); Lead Sponsor GlaxoSmithKline." https://clinicaltrials.gov/study/NCT04954859

## Same indication

- [Elebsiran](https://sec-api.dev/pdufa/elebsiran) (VIR)

Calendar months: [April 2027](https://sec-api.dev/fda-calendar/2027-04), [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/bepirovirsen.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "HIBSAGO (bepirovirsen) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/bepirovirsen

```bibtex
@misc{secapidev_pdufa_bepirovirsen_20261116,
  title        = {HIBSAGO (bepirovirsen) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/bepirovirsen}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_bepirovirsen_20261116","title":"HIBSAGO (bepirovirsen) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/bepirovirsen","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
